Search
SpyGlass Pharma Ord shs (Proposed)
SGPAdd to Watchlist
22.530USD
-0.190-0.84%
Close 07-31 16:00（ET）Quotes delayed by 15 min
753.25MMarket Cap
LossP/E TTM
More Details of SpyGlass Pharma Ord shs (Proposed) Company
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused in the development of the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company develops a non-bioerodible drug delivery technology, designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. Its lead product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System) is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma or ocular hypertension.
SpyGlass Pharma Ord shs (Proposed) Info
Ticker SymbolSGP
Company nameSpyGlass Pharma Inc
IPO dateFeb 06, 2026
CEOMooney (Patrick H)
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
Address27081 Aliso Creek Road
CityALISO VIEJO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92656
Phone13026587581
Websitehttps://spyglasspharma.com/
Ticker SymbolSGP
IPO dateFeb 06, 2026
CEOMooney (Patrick H)
Company Executives of SpyGlass Pharma Ord shs (Proposed)
Name
Name/Position
Position
Shareholding
Change
Mr. Bilal Khan
Mr. Bilal Khan
Independent Director
Independent Director
276.88K
+90.81%
Mr. Patrick Mooney
Mr. Patrick Mooney
Chief Executive Officer, Director
Chief Executive Officer, Director
183.15K
--
,
,
--
--
Dr. Malik Y. Kahook, M.D.
Dr. Malik Y. Kahook, M.D.
Co-Founder, President, Chief Medical Officer, Executive Chair of the Board and Director
Co-Founder, President, Chief Medical Officer, Executive Chair of the Board and Director
--
--
Mr. James R. Dennewill
Mr. James R. Dennewill
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Chetan Pujara, Ph.D.
Dr. Chetan Pujara, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Dr. Jean-Frederic Viret, Ph.D.
Dr. Jean-Frederic Viret, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Bilal Khan
Mr. Bilal Khan
Independent Director
Independent Director
276.88K
+90.81%
Mr. Patrick Mooney
Mr. Patrick Mooney
Chief Executive Officer, Director
Chief Executive Officer, Director
183.15K
--
,
,
--
--
Dr. Malik Y. Kahook, M.D.
Dr. Malik Y. Kahook, M.D.
Co-Founder, President, Chief Medical Officer, Executive Chair of the Board and Director
Co-Founder, President, Chief Medical Officer, Executive Chair of the Board and Director
--
--
Mr. James R. Dennewill
Mr. James R. Dennewill
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Chetan Pujara, Ph.D.
Dr. Chetan Pujara, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
FAQs
Who are the top five shareholders of SpyGlass Pharma Ord shs (Proposed)?
The top five shareholders of SpyGlass Pharma Ord shs (Proposed) are: Mr. Bilal Khan